Ray Therapeutics has just landed $100 million to attack retinitis pigmentosa, with a focus on people who have lost their vision.
Venture investors have provided $100 million in fresh funding to Ray Therapeutics, a biotech company seeking to restore vision in people with the rare blinding disease retinitis pigmentosa.
San Francisco-based Ray Therapeutics is one of several startups harnessing advances in gene therapy to attack retinitis pigmentosa. Other companies are aiming to stem the disorder before it results in blindness, among them Paris-based SparingVision and Eudora, a startup launched by San Diego- and London-based biotech company Replay Holdings.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Worldcoin Project: $100 Million Goal in SightOpenAI executive Sam Altman's project, Worldcoin, is inching towards the completion of a funding round estimated at $100 million
Les mer »
OpenAI chief Sam Altman set to raise $100 million for WorldcoinOpenAI chief Sam Altman is close to raising $100 million for his eyeball-scanning Worldcoin crypto project, report says
Les mer »
This $500 Top-Rated Vacuum Is Only $100 on Amazon TodayThis $500 Do-It-All Cordless Vacuum Is Only $100 on Amazon Right Now
Les mer »
OpenAI CEO Raising $100 Million to Scan Every Eyeball on EarthSam Altman, the CEO of OpenAI, is raising $100 million for his startup that scans eyeballs and gives out crypto.
Les mer »
The Big 3 Auction Houses Sold More Than $100 Million in Luxury Watches Over the WeekendThe pre-owned watch market is on fire. The Geneva watch auctions for Phillips, Sotheby's, and Christie's raked in a whopping $108 million. 🔥 luxurywatches watchcollectors
Les mer »